Dehydroevodiamine Protects Heart Cells from Doxorubicin Damage
Author Information
Author(s): Jie Song, Wenying Guo, Lebo Sun
Primary Institution: Ningbo Medical Center Lihuili Hospital of Ningbo University
Hypothesis
The study aims to investigate the protective effect of dehydroevodiamine (DHE) on doxorubicin-induced cardiotoxicity and its potential mechanism.
Conclusion
DHE protects cardiomyocytes against doxorubicin by regulating the NRG1/ErbB pathway.
Supporting Evidence
- DHE enhanced cardiomyocyte viability and decreased LDH release in a concentration- and time-dependent manner.
- DHE significantly inhibited doxorubicin-induced cardiomyocyte apoptosis, inflammation, and oxidative stress.
- Bioinformatics analysis showed that the protective mechanism of DHE against doxorubicin-induced cardiotoxicity was related to the ErbB signaling pathway.
Takeaway
DHE is like a superhero for heart cells, helping them stay strong and healthy even when a harmful medicine called doxorubicin is used.
Methodology
Rat H9c2 cardiomyocytes were treated with doxorubicin and dehydroevodiamine, and various assays were conducted to evaluate cell viability, apoptosis, inflammation, and oxidative stress.
Limitations
The study was conducted in vitro, and further in vivo experiments are needed to confirm the findings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website